Cited by 1,110Liver Disease Diagnosis and TreatmentInflammasome and immune disordersLiver physiology and pathology

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice

Open access

Mridha, Auvro R., Wree, Alexander, Robertson, Avril A.B., Yeh, Matthew M., Johnson, Casey D., Van Rooyen, Derrick M., Haczeyni, Fahrettin, Teoh, Narci C.-H., Savard, Christopher, Ioannou, George N., Masters, Seth L., Schroder, Kate, Cooper, Matthew A., Feldstein, Ariel E., Farrell, Geoffrey C.·2017·Journal of Hepatology

DOI 10.1016/j.jhep.2017.01.022PMC PMC6536116

Open this paper in CoChat — free account

Abstract

Background & aims NOD-like receptor protein 3 (NLRP3) inflammasome activation occurs in Non-alcoholic fatty liver disease (NAFLD). We used the first small molecule NLRP3 inhibitor, MCC950, to test whether inflammasome blockade alters inflammatory recruitment and liver fibrosis in two murine models of steatohepatitis.Methods We fed foz/foz and wild-type mice an atherogenic diet for 16weeks, gavaged MCC950 or vehicle until 24weeks, then determined NAFLD phenotype. In mice fed an methionine/choline deficient (MCD) diet, we gavaged MCC950 or vehicle for 6weeks and determined the effects on liver fibrosis.Results In vehicle-treated foz/foz mice, hepatic expression of NLRP3, pro-IL-1β, active caspase-1 and IL-1β increased at 24weeks, in association with cholesterol crystal formation and NASH pathology; plasma IL-1β, IL-6, MCP-1, ALT/AST all increased. MCC950 treatment normalized hepatic caspase 1 and IL-1β expression, plasma IL-1β, MCP-1 and IL-6, lowered ALT/AST, and reduced the severity of liver inflammation including designation as NASH pathology, and liver fibrosis. In vitro, cholesterol crystals activated Kupffer cells and macrophages to release IL-1β; MCC950 abolished this, and the associated neutrophil migration. MCD diet-fed mice developed fibrotic steatohepatitis; MCC950 suppressed the increase in hepatic caspase 1 and IL-1β, lowered numbers of macrophages and neutrophils in the liver, and improved liver fibrosis.Conclusion MCC950, an NLRP3 selective inhibitor, improved NAFLD pathology and fibrosis in obese diabetic mice. This is potentially attributable to the blockade of cholesterol crystal-mediated NLRP3 activation in myeloid cells. MCC950 reduced liver fibrosis in MCD-fed mice. Targeting NLRP3 is a logical direction in pharmacotherapy of NASH.Lay summary Fatty liver disease caused by being overweight with diabetes and a high risk of heart attack, termed non-alcoholic steatohepatitis (NASH), is the most common serious liver disease with no current treatment. There could be several causes of inflammation in NASH, but activation of a protein scaffold within cells termed the inflammasome (NLRP3) has been suggested to play a role. Here we show that cholesterol crystals could be one pathway to activate the inflammasome in NASH. We used a drug called MCC950, which has already been shown to block NLRP3 activation, in an attempt to reduce liver injury in NASH. This drug partly reversed liver inflammation, particularly in obese diabetic mice that most closely resembles the human context of NASH. In addition, such dampening of liver inflammation in NASH achieved with MCC950 partly reversed liver scarring, the process that links NASH to the development of cirrhosis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2017.01.022

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Inflammasomes
Schroder, K., & Tschopp, J. (2010) · Cell · doi:10.1016/j.cell.2010.01.040 · Cited by 5,475
Self-citation
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., Abela, G. S., Franchi, L., Nuñez, G., Schnurr, M., et al. (2010) · Nature · doi:10.1038/nature08938 · Cited by 4,026
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases
Coll, R. C., Robertson, A. A. B., Chae, J. J., Higgins, S. C., Muñoz-Planillo, R., Inserra, M. C., Vetter, I., Dungan, L. S., Monks, B. G., Stutz, A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3806 · Cited by 2,849
Self-citation
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., Thaiss, C. A., Kau, A. L., Eisenbarth, S. C., Jurczak, M. J., et al. (2012) · Nature · doi:10.1038/nature10809 · Cited by 2,435
A lipidomic analysis of nonalcoholic fatty liver disease
Puri, P., Baillie, R. A., Wiest, M. M., Mirshahi, F., Choudhury, J., Cheung, O., Sargeant, C., Contos, M. J., & Sanyal, A. J. (2007) · Hepatology · doi:10.1002/hep.21763 · Cited by 1,338
Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites†
Neuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077
Cholesterol Crystals Activate the NLRP3 Inflammasome in Human Macrophages: A Novel Link between Cholesterol Metabolism and Inflammation
Rajamäki, K., Lappalainen, J., Öörni, K., Välimäki, E., Matikainen, S., Kovanen, P. T., & Eklund, K. K. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011765 · Cited by 1,039
NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice
Wree, A., Eguchi, A., McGeough, M. D., Pena, C. A., Johnson, C. D., Canbay, A., Hoffman, H. M., & Feldstein, A. E. (2014) · Hepatology · doi:10.1002/hep.26592 · Cited by 945
Self-citation
Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications
Cusi, K. J. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.02.003 · Cited by 940

Show all 49 references

Sorted by citations

Items 901–999 of 999

A patent review of NLRP3 inhibitors for inflammatory diseases (2023-present)
Namme, J. N., Xu, Y., McClendon, E., Zhang, C. M., & Zhang, S. (2026) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2026.2656161 · Cited by 2
UPLC-Q-TOF/MS-Based Metabolomics and 16S rRNA Profiling Reveal that Corosolic Acid Ameliorates High-Fat Diet-Induced MASLD by Modulating the Gut-Liver Axis to Inhibit the cGAS-STING Pathway
Cai, K., Chen, Z., Deng, S., Chen, J., Yu, J., Zhang, X., Jia, W. P., Huang, A., Chen, Y., Xie, Z., et al. (2026) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.5c13513 · Cited by 2
Traditional Chinese Medicine Modulation of the Gut–Liver Axis: From Barrier Disruption to Inflammasome Activation in MASLD/MASH
Ren, L., He, Q., Hu, Z., Jin, J., & 陶飞宝 (2026) · Journal of Visualized Experiments · doi:10.3791/70259 · Cited by 2
Advances in the interplay between mechanical forces and inflammatory immunity in keloid formation
Zhou, S., Wang, L., Chen, N., Liu, J., Zhang, R., Zhou, S., Liu, Y., Zhu, W., Chen, X., & Meng, R. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1792028 · Cited by 2
The NLRP3 inflammasome in metabolic dysfunction-associated steatotic liver disease: role and advances in therapeutic targeting
Wei, S., He, Y., Luo, C., & He, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1924392 · Cited by 4
Molecular mechanisms and pathogenesis of MASH
Gallage, S., Govaere, O., Anstee, Q. M., Shulman, G. I., Tacke, F., & Heikenwälder, M. F. (2026) · Nature · doi:10.1038/s41586-026-10529-0 · Cited by 3
Sex hormones abnormalities in non-alcoholic fatty liver disease: pathophysiological and clinical implications
Vincenzo, A. D., Russo, L., Doroldi, C. G., Vettor, R., & Rossato, M. (2021) · Exploration of Medicine · doi:10.37349/emed.2021.00049 · Cited by 2
Pharmacology of NASH
Albhaisi, S. A. M., & Sanyal, A. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00121-3 · Cited by 2
Current NASH Pathogenesis and Diagnostic Techniques and Treatments
Dai, L. (2023) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v36i.6281 · Cited by 2
The challenging role of micro-RNAs in non-alcoholic fatty liver disease in children with obesity: is it time for a new era?
Bartiromo, M., Nardolillo, M., Ferrara, S., Russo, G., del Giudice, E. M., & Sessa, A. D. (2023) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2023.2242245 · Cited by 2
The role of interleukin-20 in liver disease: Functions, mechanisms and clinical applications
Wang, K., Zhan, H.-Q., Hu, Y., Yuan, Z.-Y., Yang, J., Yang, D., Tao, L.-S., & Xu, T. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e29853 · Cited by 4
Hepatocyte-specific RIG-I loss attenuates metabolic dysfunction-associated steatotic liver disease in mice via changes in mitochondrial respiration and metabolite profiles
Seok, J. K., Yang, G., Jee, J. I., Kang, H. C., Cho, Y., Lee, H. S., & Lee, J. Y. (2024) · Toxicological Research · doi:10.1007/s43188-024-00264-x · Cited by 2
Demethyleneberberine ameliorates pulmonary fibrosis by inhibiting the NLRP3 inflammasome and the epithelial–mesenchymal transition
Wang, X., Wu, X., Zhou, L., Lin, Y., Tang, Z., Chen, C., Wang, B., & Lin, Y.-T. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115003 · Cited by 2
Effects of L-carnitine over-supplementation on spermatogenesis and sperm function in healthy NMRI mice
Jabarineitapeh, M., Naderi, N., Tavalaee, M., & Nasr‐Esfahani, M. H. (2025) · Tissue and Cell · doi:10.1016/j.tice.2025.103014 · Cited by 2
β-sitosterol attenuates hepatic lipid accumulation and fibrosis via NLRP3 signaling in MASH mice
Wang, X., Wang, K., Gao, W., Liu, Z., Zhou, J., Feng, T., & Chen, Y. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04614-w · Cited by 2
Programmed cell death and liver diseases
Онищенко, Н. А., Гоникова, З. З., Nikolskaya, A. O., Кирсанова, Л. А., & Sevastianov, V. I. (2022) · Russian Journal of Transplantology and Artificial Organs · doi:10.15825/1995-1191-2022-1-72-88 · Cited by 3
Inflammasome-induced inflammation and fibrosis in liver
Kaufmann, B. K., Kim, A. D., & Feldstein, A. E. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91802-2.00017-7 · Cited by 2
Self-citation
In Vitro Evaluation of A Hybrid Drug-Delivery Nanosystem for Fibrosis Prevention In Cell Therapy for Type 1 Diabetes
Rennie, C., Huang, Y., Siwakoti, P., Du, Z., Padula, M. P., Bao, G., Tuch, B. E., Xu, X., & McClements, L. (2023) · Nanomedicine · doi:10.2217/nnm-2022-0231 · Cited by 2
Pharmacotherapeutics for cytokine storm in COVID-19
Pal, R., & Chaudhary, M. J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95545-4.00003-7 · Cited by 2
Caffeine, coffee and effects on the liver
Alegret, M., Laguna, J. C., & Roglans, N. (2024) · Coffee in Health and Disease Prevention · doi:10.1016/b978-0-443-13868-3.00001-6 · Cited by 1
Identification of diagnostic markers pyrodeath-related genes in non-alcoholic fatty liver disease based on machine learning and experiment validation
Lei, L., Li, J., Liu, Z., Zhang, D., Liu, Z., Wang, Q., Gao, Y., Mo, B., & Li, J. (2024) · Scientific Reports · doi:10.1038/s41598-024-77409-3 · Cited by 1
NLRP3 inflammasome activation contributes to acute liver injury caused by CVA6 infection in mice
Xie, Y., Hu, Q., Duan, G., Wang, F., Feng, F., Li, D., Jiang, W., Ji, W., Zhu, P., Zhang, X., et al. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-10136-2 · Cited by 1
Identification of pyroptosis-associated gene to predict fibrosis and reveal immune characterization in non-alcoholic fatty liver disease
Tu, S., Xi, J., Bu, X., Zhang, Q., Liao, S., Zhu, X., Guo, Y., & Sha, W. (2025) · Scientific Reports · doi:10.1038/s41598-025-96158-5 · Cited by 1
Cholesterol and the gut-liver axis: unraveling their role in the onset and progression of metabolic-associated steatotic liver disease
Rodríguez-Rojas, L. A., Bucio, L., Souza-Arroyo, V., Gutiérrez‐Ruíz, M. C., Gómez-Quiroz, L. E., & Miranda-Labra, R. U. (2025) · Exploration of Digestive Diseases · doi:10.37349/edd.2025.100583 · Cited by 1
Macrophage Nogo-B Drives Liver Fibrosis
Zhang, L., Ni, M., Si, J., Cheng, F., Zhang, L., Liang, Y., Liu, M., Li, W., Li, J., Chi, Y., et al. (2026) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2025.101622 · Cited by 1
Resistance to silicosis progression in mice with Ch25h downregulation: The involvement of NLRP3 inflammasome
Sun, M., Fang, H., Zhang, J., Wang, M., Peng, J. C., Ma, L., Jin, H., & Zhang, W. (2025) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2025.106861 · Cited by 1
The Cannabinoid System as a Potential Novel Target for Alcohol‐Associated Liver Disease: A Propensity‐Matched Cohort Study
Fakhoury, B., Jahagirdar, V., Rama, K., Hudson, D., Wang, W., Díaz, L. A., & Arab, J. P. (2025) · Liver International · doi:10.1111/liv.70401 · Cited by 1
Inhibition of NLRP3 inflammasome activation alleviated liver injury and wasting effect in tumor-bearing mice
Wu, S., Cheng, Q., Shi, Y., Liu, M., Tan, K., & Liao, B. (2025) · Scientific Reports · doi:10.1038/s41598-025-23323-1 · Cited by 1
Ticagrelor attenuates cholestasis-induced liver fibrosis by inhibiting S1PR2-dependent Akt/ERK signaling, NLRP3 inflammasome activation
El-Maadawy, W. H., Amer, M., Mostafa, A., Hassany, A. A., Shafie, N. S., Lethy, A. W., El-Ahwany, E. G., & Hafiz, E. O. A. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115834 · Cited by 1
MASLD: Lipotoxicity and Imaging Parallels from Liver Steatosis to Kidney Injury
Săndulescu, S. M., Ghiga, D. Ș., Tudoraşcu, D. R., Săndulescu, L., Mită, A., Urhuț, M. C., & Taisescu, C. I. (2025) · Life · doi:10.3390/life15121805 · Cited by 3
The Thyroid Twist: How GLP-1 Agonists Are Influencing Autoimmune Thyroid Care
Mazza, A. D. (2025) · Cureus · doi:10.7759/cureus.98153 · Cited by 3
Alisol F 24-acetate attenuated metabolic dysfunction-associated steatohepatitis by targeting the KEAP1/NRF2-mediated macrophage pyroptosis
Dong, Z., Huang, K., Wu, W., Xing, L., Zhang, Y., Zhang, X., Yang, W., & Zhao, K. (2026) · Chinese Medicine · doi:10.1186/s13020-025-01322-8 · Cited by 1
Ecliptasaponin A alleviates inflammation and fibrosis in experimental MASH mice via targeting the NLRP3 inflammasome and YAP signaling pathway
Gao, K., Wei, Z., Zhao, M., Xu, D., Tao, X., Guo, C., Du, Y., Jin, F., Li, W., Liu, M., et al. (2026) · Chinese Medicine · doi:10.1186/s13020-025-01321-9 · Cited by 1
New Insights of Punicalagin in Alleviating Diabetic Liver Injury: Inhibition of NEK7 ‐ NLRP3 via Modulating Mitochondrial Dynamics
Tan, X., Zhang, R., Zhang, Y., You, Z., & Yang, L. (2026) · Phytotherapy Research · doi:10.1002/ptr.70208 · Cited by 1
SIRT3 ameliorates hepatic inflammation, oxidative stress, and fibrosis in HFD- or MCD diet-fed mice
Lv, H., Sun, W., Tian, C., Bian, C., Lu, Z., & Guo, X. (2026) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2026.110276 · Cited by 1
The role of NLRP3 inflammasome in opioid-induced neurochemical markers, therapeutic effects, and adverse effects in male mice
Rodriguez, M., Veeragoni, D., Carbajal, C., Owens, F., Eans, S. O., Williams, A. K., Shinouchi, R., McLaughlin, J. P., & El‐Hage, N. (2026) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2026.106528 · Cited by 1
Harnessing the River Red Gum: A promising nano-delivery for optimal therapeutic effect against HFD-induced non-alcoholic steatohepatitis (NASH) in rats
Mohammed, D. M., Baker, D. H. A., & Korany, R. M. S. (2026) · Food Bioscience · doi:10.1016/j.fbio.2026.108604 · Cited by 1
The role and possible mechanism of intestinal fungi in the progression of chronic liver diseases
Hu, Y. H., Yang, Y., Wang, S., & Chu, H. (2026) · npj Biofilms and Microbiomes · doi:10.1038/s41522-026-00961-5 · Cited by 4
Cholesterol-rich diet exacerbates steatohepatitis in the STAM mouse model
Jonas, W., Gottmann, P., Jähnert, M., Baer, N. B., Schürmann, A., & Vogel, H. (2026) · Scientific Reports · doi:10.1038/s41598-026-45979-z · Cited by 1
Natural Product Treatment for Metabolic Dysfunction-Associated Steatotic Liver Disease: Targeted Mitochondrial Quality Control
Liu, J., Li, F., Zeng, Q., Hu, W., Yang, L., Luo, S., Lv, F., Li, D., & Deng, Y. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s610273 · Cited by 1
Emerging Therapeutic Perspectives in Obese Patients with MASLD Leading to Compensated Advanced Chronic Liver Disease
Chianetta, R., Giannitrapani, L., Lipari, A. G., Brunone, A., Cannizzo, C., Citarrella, R., Soresi, M., Liguori, A., Panera, N., Morisco, F., et al. (2026) · Biomolecules · doi:10.3390/biom16060797 · Cited by 1
Ligustrum lucidum polysaccharide ameliorated immune mediated inflammatory responses by regulating both the cGAS STING pathway and the inflammasome
Li, J., Xu, Y., Wen, J., Wang, Y., Ma, F.-Z., Su, K., Wang, T.-T., Zhang, G., Hu, Z.-J., Xiao, X.-H., et al. (2026) · Journal of Functional Foods · doi:10.1016/j.jff.2026.107364 · Cited by 1
Trained immunity as a systemic bridge: the liver-gut-immune-oral axis in the comorbidity of chronic liver disease and periodontitis
Li, X., Lv, G., Yuan, D., Hu, J., Lou, W., Tu, Y., Zhou, J., & Qin, R. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1855561 · Cited by 1
Huanglian wendan decoction attenuates hepatic inflammation and lipogenesis via inhibition of the NF-κB/HDAC1/SREBP-1c axis
Fan, W., Zhou, F., Song, Q., Liu, L., Huang, S., Pan, J., Zhang, Y., Yang, Q., Pan, M., & Zhang, Y. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.121984 · Cited by 1
TCM‐Guided Targeted Therapies Against NLRP3 Inflammasome in NAFLD
Zhang, Y. (2026) · Immunity Inflammation and Disease · doi:10.1002/iid3.70474 · Cited by 1
Rutin attenuates liver fibrosis via the IRG1-itaconate-Nrf2 axis
Jiang, N., Zhang, J., Kuang, G., Liu, G., Wan, J., Wang, B., & Zhao, Z. (2026) · Inflammation Research · doi:10.1007/s00011-026-02298-3 · Cited by 1
A translational model of MASLD-associated HFpEF defines mitochondrial dysfunction and cardiac plasticity during disease progression and regression
Ganguly, S., Gunes, B. B., Gu, Y., Suárez, J., Gupta, G., Ishizuka, K., Murad, R., Kisseleva, T., Dillmann, W. H., Peterson, K. L., et al. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156682 · Cited by 2
Inflammation-mediated diabetes-liver disease cross-organ crosstalk: From molecular mechanisms to precision therapeutic strategies
Guo, Y., Ma, Q., Guo, Z., Chu, J., Wu, N., & Yajuan, Q. I. (2026) · Life Sciences · doi:10.1016/j.lfs.2026.124534 · Cited by 1
Mechanism and regulation of programmed cell death in aging-related diseases
Xie, X., & Xu, D. (2026) · Cell chemical biology · doi:10.1016/j.chembiol.2026.06.005 · Cited by 1
Beyond cardiovascular protection: a conceptual and translational review of the hepato-specific mechanisms of statins in metabolic dysfunction-associated steatotic liver disease (MASLD)
Jiménez-González, C., Iruzubieta, P., Alonso‐Peña, M., Cayon, L., & Crespo, J. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1884657 · Cited by 1
Autophagy in MASLD : A Metabolic and Precision Medicine Perspective
Cazzaniga, A., Frigo, S., Cherubini, A., Rrapaj, E., & Valenti, L. V. C. (2026) · Liver International · doi:10.1111/liv.70816 · Cited by 1
Obeticholic acid as an index farnesoid X receptor scaffold in metabolic dysfunction-associated steatohepatitis: a testable model for efficacy-liability separation and biomarker interpretation
Liu, J., & Wu, X. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1879097 · Cited by 1
Therapeutic Mechanisms of Resmetirom and Semaglutide in MASLD/MASH: A Review of Inflammatory and Fibrotic Metabolites
Toshikuni, N. (2026) · Metabolites · doi:10.3390/metabo16080586 · Cited by 1
Immune cell balance as potential biomarker of progressing non-alcoholic fatty liver disease
Topchieva, L. V., Валерьевна, К. И., Дуданова, О. П., Vasileva, A., & Жулай, Г. А. (2024) · Genes and Cells · doi:10.17816/gc610252 · Cited by 2
[Adeno-associated virus-mediated hepatocyte-specific NDUFA13 overexpression protects against CCl4-induced liver fibrosis in mice by inhibiting hepatic NLRP3 activation].
Xu, X., Feng, J., Luo, Y., He, X., Zang, J., & Huang, D. (2024) · PubMed · doi:10.12122/j.issn.1673-4254.2024.02.01 · Cited by 1
Exploring Mechanisms of Lang Qing Ata in Non-Alcoholic Steatohepatitis Based on Metabolomics, Network Pharmacological Analysis, and Experimental Validation
Li, S., Zhu, H., Zhai, Q., Hou, Y., Yang, Y., Lan, H., Jiang, M., & Xuan, J. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s503757 · Cited by 1
Unraveling the Converging Roles of ASC-Dependent Inflammasomes, Interleukin-1 Superfamily Members, Serum Amyloid A, and Non-Sterile Inflammation in Disease Pathology and Fibrosis in Inflammatory Bowel Disease and Primary Sclerosing Cholangitis
Losa, M., Schwarzfischer, M., Emmenegger, M., Spalinger, M. R., Rogler, G., & Scharl, M. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26168042 · Cited by 2
Current Models of Fatty Liver Disease; New Insights, Therapeutic Targets and Interventions
Jonscher, K. R., & Bruce, K. D. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-12668-1_3 · Cited by 1
From fatty liver to nonalcoholic steatohepatitis with fibrosis
Muriel, P. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99764-5.00013-5 · Cited by 1
Tratamiento perioperatorio del paciente diabético adulto
Raucoules-Aimé, M., & Ouattara, T. N. T. (2023) · EMC - Anestesia-Reanimación · doi:10.1016/s1280-4703(22)47395-6 · Cited by 1
A novel role of RNase L in the development of nonalcoholic steatohepatitis
Chen, G., Zhao, X., Dankovskyy, M., Ansah-Zame, A., Alghamdi, U. M., Liu, D., Wei, R., Zhao, J., & Zhou, A. (2023) · The FASEB Journal · doi:10.1096/fj.202300621r · Cited by 1
Bone morphogenetic protein-9/activin-like kinase 1 axis a new target for hepatic regeneration and fibrosis treatment in liver injury
Marı́, M., & Morales, A. (2017) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn.2017.11.02 · Cited by 1
Lipotoxicity in Non-alcoholic Fatty Liver Disease: Mechanisms and Prevention in Experimental Models
Geng, Y. (2020) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.130260314 · Cited by 2
Single-Cell Transcriptomic Analysis of Livers During NLRP3 Inflammasome Activation Reveals a Novel Immune NichePreprint
Calcagno, D. M., Chu, A., Gaul, S., Taghdiri, N., Toomu, A., Leszczynska, A., Kaufmann, B. K., Wree, A., Geisler, L. J., Hoffman, H. M., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.31.437725 · Cited by 1
Self-citation
Therapeutic Approaches for Nonalcoholic Steatohepatitis ( NASH )
Glatthar, R., & Arch, R. H. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc274 · Cited by 1
Les feuilles mortes
Kosma, J. (1945) · DigitalCommons (California Polytechnic State University) · Cited by 1
Circulating Perturbation of Phosphatidylcholine (Pc) and Phosphatidylethanolamine (Pe) is Associated to Cardiac Remodeling and Nlrp3 Inflammasome in Cardiovascular Patients with Insulin Resistance RiskPreprint
Vianello, E., Ambrogi, F., Kalousová, M., Badalyan, J., Dozio, E., Tacchini, L., Schmitz, G., Zima, T., & Romanelli, M. M. C. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4475282 · Cited by 1
Induction of NASH in the Nwd1 −/− mouse liver via SERCA2-dependent endoplasmic reticulum stressPreprint
Yamada, S., Nakadate, K., Mizukoshi, T., Kawakami, K., Kobayashi, R., Horii, T., Hatada, I., & Sakakibara, S. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.26.577307 · Cited by 1
Chiglitazar, the first pan-PPAR agonist approved globally, shows potential to treat metabolic dysfunction–associated steatohepatitis in vitro and in vivoPreprint
Deng, S., Li, S., Zhang, Q., Mao, X., Pan, D., Yang, X., & Huang, S. (2024) · Research Square · doi:10.21203/rs.3.rs-4413947/v1 · Cited by 1
Caspase-1 self-terminates protease activity to enforce homeostasis and prevent inflammasome-driven diseasesPreprint
Burgener, S. S., Milner, M. T., Dey, S., Morgan, P. K., Blackmore, D. G., Frampton, E., Miller, G. C., de Oliveira, M. D., Kenney, K. M., Bajracharya, R., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.28.651119 · Cited by 1
Self-citation
CDK5RAP3 Deficiency Exacerbates Hepatic Inflammation via NLRP3 Inflammasome-Mediated Pyroptosis and Apoptotic CrosstalkPreprint
Chen, X., Huang, Y., Wu, Y., Sheng, L., Yan, H., Chen, F., Li, F., Ketema, H., & Cai, Y. (2025) · Preprints.org · doi:10.20944/preprints202506.2315.v1 · Cited by 1
Gut microbiota-derived indole-3 acetic acid mitigates key hallmarks of metabolic dysfunction-associated steatotic liver disease (MASLD) in an NLRP3-dependent manner in in vitro and diet-induced mouse modelsPreprint
Sharma, P. K., Kumar, L., Baghel, A., Jana, P., Dhar, K., Bansal, R., Goswami, Y., Kumari, A., Yadav, R., Shalimar, S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.25.701562 · Cited by 1
Liver Cirrhosis with Steatohepatitis: Nonalcoholic Steatohepatitis and Alcoholic Steatohepatitis
Miyake, T., & Hiasa, Y. (2019) · Springer eBooks · doi:10.1007/978-981-13-7979-6_1
Role of extracellular vesicles in hypoxia-induced hepatic injury in non-alcoholic fatty liver disease
Villanueva, A. H. (2021) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.180853744
Culture and Characterization of Kefir Organisms to Reproduce the Health Benefits of Traditional Kefir
Bourrie, B. C. T. (2020) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3-p44t-f154
Cell therapy for acute mesenteric ischemia and other vascular diseases
Андреевич, В. И., Khachatryan, E. O., Александрович, А. А., Иванович, Ч. А., & Gasanov, E. N. (2021) · Russian Journal of Cardiology and Cardiovascular Surgery · doi:10.17116/kardio202114041276
TGF-β activates NLRP3 Inflammasome by an Autocrine Production of TGF-β in LX-2 Human Hepatic Stellate CellsPreprint
Oh, Y. S., Kang, H., Seo, E., & Jun, H. (2021) · Research Square · doi:10.21203/rs.3.rs-888943/v1
Ginkgolide protects against ethanol-induced gastric ulcer in rats through NLRP3 related pathway
Liu, G.-N., & Men, W. (2022) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v30.i2.77
Targeting of macrophages and hepatic stellate cells for the treatment of liver diseases
Kurniawan, D. W. (2022) · doi:10.3990/1.9789036553445
Yunpi Qushi Jiangzhuo Recipe Alleviates Lipid Deposition and Reduces Liver Damage in Mice with Non-alcoholic Fatty Liver Disease
Wu, X., Zhu, L., You, M., Chen, Y., Chai, H., Chen, L., Qian, Q., Shangguan, Z., Jiang, F., Li, S., et al. (2022) · Clinical Complementary Medicine and Pharmacology · doi:10.1016/j.ccmp.2022.100050
From inflammation to fibrosis
Muriel, P. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99764-5.00010-x
Gestione perioperatoria del paziente diabetico adulto
Raucoules-Aimé, M., & Ouattara, T. N. T. (2023) · EMC - Anestesia-Rianimazione · doi:10.1016/s1283-0771(22)47366-x
Gsk3β deficiency in macrophages alleviates the progression of nonalcoholic steatohepatitis by promoting PINK1-mediated mitophagic autophagy α β γPreprint
zhang, Z., Li, J., Kong, X., Sun, X., Deng, Z., Tang, W., Zhou, H., Ni, M., & Xia, Y. (2023) · Research Square · doi:10.21203/rs.3.rs-2661020/v1
Marrubium persicum İmproved the Biological Parameters Associated with Angiogenesis and İnflammation in Mice.
Fekri, K., Mortezaie, M. S., Maleki‐Dizaji, N., Fathiazad, F., & Hamedeyazdan, S. (2023) · PubMed Central · doi:10.22092/ari.2022.358579.2253
NLRP3 inflammasome inhibition of OP9 cells enhance therapy for inflammatory bowel disease
Chen, Y., Meng, W., Ren, G., An, N., Zhang, J., Liu, Z., Wu, X., Yin, W., Hu, X., Liu, Z., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e18038
Immunology of gut microbiome and liver in non-alcoholic fatty liver disease (NAFLD): mechanisms, bacteria, and novel therapeutic targetsPreprint
Gruzdev, S., Viktorovna, P. I., & Anatolievna, G. O. (2023) · doi:10.22541/au.169332662.25916191/v1
The Role of Neutrophil Extracellular Traps (NETs) in Non-alcoholic Fatty Liver Disease (NAFLD): A Comprehensive Analysis of NETs-related GenesPreprint
Fang, Z., Yu, X., Liu, C., Yang, K., Ji, Y., & Liu, C. (2024) · Research Square · doi:10.21203/rs.3.rs-3804984/v1
Screening of common key immune genes and prediction of potential drugs in chronic hepatic injuryPreprint
Pang, T., Fu, J., Li, J., Chen, Y., He, H., Ma, J., Cao, L., Tang, Q., Hu, N., Zhao, M., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-3872787/v1
Community Series - Liver Fibrosis and MAFLD: from Molecular Aspects to Novel Pharmacological Strategies, Volume II
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-4473-0
Cannabidiol may prevent the development of congestive hepatopathy secondary to right ventricular hypertrophy associated with pulmonary hypertension in rats
Krzyżewska, A., Baranowska‐Kuczko, M., Galicka, A., Kasacka, I., Mińczuk, K., & Kozłowska, H. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00579-4
Additional file 1 of Lentinan alleviates arsenic-induced hepatotoxicity in mice via downregulation of OX40/IL-17A and activation of Nrf2 signaling
Yang, Y., Song, S., Nie, Y., Chen, R., & Chen, P. (2022) · Figshare · doi:10.6084/m9.figshare.19395805
Role of Kupffer cells and other immune cells
Puengel, T., & Tacke, F. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95262-0.00024-3
Vinpocetine represses the progression of nonalcoholic steatohepatitis in mice by mediating inflammasome components via NF-κB signaling
Zhu, Y., Tang, H., Zhao, H., Lu, J. G., Lin, K., Ni, J., Zhao, B., Wu, G., & Tan, C. (2024) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2023.07.006
Lipan Strain and Ab Zebrafish Embryos Used to Reveal Toxic Effects of AcetaminophenPreprint
Xie, S., Gao, L., Chen, L., Cheng, Z., & Zhang, X. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4868116
NLRP1 is activated by palmitic acid and induced in human metabolic dysfunction-associated steatohepatitisPreprint
Pinilla, M., Baños, E. C., Martínez‐Sánchez, M. A., Sánchez‐Villalobos, M., Oliva‐Bolarín, A., Rico‐Chazarra, S., Ruiz‐Alcaraz, A. J., Martínez, C. M., Mika, A., Frutos, M. D., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.11.622769
Comparison of the effects of hydroalcoholic extract of Dracocephalum kotschyi and silymarin on diclofenac-induced hepatotoxicity in rats: inflammation signaling HMGB1, NLRP3, IL1BPreprint
Soogh, E. H., Saghaei, F., & Saghaei, F. (2024) · Research Square · doi:10.21203/rs.3.rs-5403870/v1
Liver Steatosis: From Lipotoxicity to Cellular Damage
Puengel, T., & Tacke, F. (2024) · Springer eBooks · doi:10.1007/978-981-97-9519-2_4 · Cited by 2
Toll-Like Receptors, PAMPs, and DAMPs in Hepatotoxicity
Zhang, Y., Kim, S. J., Zhang, H., & Tsung, A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00270-9
Effects of Justicia carnea leaf extract on cerebral oxidative stress parameters and expression of cellular adhesion molecule-1 in albino mice exposed to TNBS
Enaohwo, M. T., Orororo, O. C., Basil-Iwhiwhu, O. P., Jaiyeoba-Ojigho, J. E., Dunkwu, C. C., Enyi, K. C., & Mode, J. (2025) · The Journal of Basic and Applied Zoology · doi:10.1186/s41936-025-00445-6 · Cited by 2

Authors: Mridha, A. R., Wree, A., Robertson, A. A. B., Yeh, M. M., Johnson, C. D., Van Rooyen, D. M., Haczeyni, F., Teoh, N. C.-H., Savard, C., Ioannou, G. N., Masters, S. L., Schroder, K., Cooper, M. A., Feldstein, A. E., & Farrell, G. C.
Affiliations: Australian National University (AU)
University of California San Diego (US)
The University of Queensland (AU)
University of Washington (US)
Walter and Eliza Hall Institute of Medical Research (AU)
Corresponding author: Farrell, Geoffrey C.
ORCID: Mridha, Auvro R.
Wree, Alexander
Robertson, Avril A.B.
Yeh, Matthew M.
Johnson, Casey D.
Haczeyni, Fahrettin
Savard, Christopher
Ioannou, George N.
Masters, Seth L.
Schroder, Kate
Cooper, Matthew A.
Feldstein, Ariel E.
Venue: Journal of Hepatology
Publisher: Elsevier BV
Published: 2017-05
Volume: 66
Issue: 5
Pages: 1037-1046
ISSN: 0168-8278 (ISSN-L)
DOI: 10.1016/j.jhep.2017.01.022
PMC: PMC6536116
OpenAlex: W2585046292
Cited by: 1,110
References: 49
Citations by year: 2026: 117 · 2025: 147 · 2024: 126 · 2023: 150 · 2022: 160 · 2021: 143 · 2020: 121 · 2019: 61 · 2018: 70 · 2017: 14
FWCI: 57.20
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Journal of Hepatology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
ANU Open Research (Australian National University) (submittedVersion, cc-by-nc-nd)
RWTH Publications (RWTH Aachen) (submittedVersion)
Funders: National Institute on Alcohol Abuse and Alcoholism (U01AA022489, R21AA023574)
National Institute of Diabetes and Digestive and Kidney Diseases (R01DK113592)
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords: NLRP3 inflammasome, MCC950, nonalcoholic steatohepatitis, liver fibrosis, liver inflammation, IL-1β, caspase-1, cholesterol crystals, Kupffer cells, macrophages, neutrophil migration, methionine-choline-deficient diet, atherogenic diet, myeloid cells
MeSH terms: NLR Family, Pyrin Domain-Containing 3 Protein, Animals, Disease Models, Animal, Female, Furans, Hepatitis, Heterocyclic Compounds, 4 or More Rings, Indenes, Liver Cirrhosis, Experimental, Sulfonamides, Sulfones, NF-kappa B, Reactive Oxygen Species, Mice, Interleukin-1beta, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks